Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002037 · ClinicalTrials.gov registry record · NA
Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study
A NA study, sponsored by Amgen.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT00002037 is a NA study that has completed, run by Amgen. The registered enrollment target is 15 participants.
The verdict
NCT00002037, a NA study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
To examine the effectiveness of subcutaneous gamma interferon in reducing severity of Mycobacterium avium- intracellulare (MAI) bacillemia episodes in AIDS patients in an open-label dose-randomized multi-center pilot clinical investigation. To evaluate the safety of gamma interferon given by subcutaneous injection (SC) in the AIDS patient in the presence and absence of AZT therapy.
Interventions
- DRUG Trifluridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002037
The ClinicalTrials.gov registry entry for NCT00002037 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Trifluridine is the first listed.
NCT00002037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002037 about?
NCT00002037 is a clinical study titled "Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study". To examine the effectiveness of subcutaneous gamma interferon in reducing severity of Mycobacterium avium- intracellulare (MAI) bacillemia episodes in AIDS patients in an open-label dose-randomized multi-center pilot clinical investigation. To evaluate the safety of gamma interferon given by subcuta...
What is the current status of trial NCT00002037?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants.
What interventions are being tested in trial NCT00002037?
The interventions under investigation include: Trifluridine (DRUG).
Who is sponsoring clinical trial NCT00002037?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.